Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Assertio Holdings, Inc.NASDAQ: ASRT

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 3.7% from a year ago

Cash & equivalents stood at $33.71M at the end of Q1 FY2026, down 3.7% from a year earlier and up 229.6% from the prior quarter. Over 3 fiscal years it compounded at -46.0% a year.

Context

  • Cash & equivalents amounted to 16.0% of total assets at the end of Q1 FY2026, up 3.7 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -3.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$33.71M+229.6% QoQ
Last fiscal yearDec 2025
$10.23M-79.8% YoY
Year agoMar 2025
$35M-3.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.7%——
1 year-79.8%——
3-year CAGR-46.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
10.23M USD
Year-over-year change
-79.8%
4-year CAGR
-27.4%

Cash & Equivalents vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -3.7% is the 4th highest of 10, against a peer median of -16.9%.
  • Cash & equivalents amounts to 16.0% of total assets for ASRT, versus a peer median of 51.3%.
ASRT Competitors
Cash & Equivalents for ASRT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FBIOFortress Biotech, Inc.Mar 2026$255.84M USD+180.1%-23.6%71.7%
TCRXTScan Therapeutics, Inc.Mar 2026$128.06M USD-16.9%+8.3%63.4%
XBITXBiotech Inc.Mar 2026$115.46M USD-25.9%-7.2%82.6%
LUNGPulmonx CorporationMar 2026$61.57M USD-17.4%-11.7%51.3%
VXRTVaxart, Inc.Mar 2026$50.75M USD+76.8%+6.9%28.2%
INCRInterCure Ltd.Dec 2025₪46.47M ILS-40.7%-41.5%6.7%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$39.13M USD-23.8%-29.5%40.5%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$34.06M USD-13.0%+12.0%31.6%
ASRTAssertio Holdings, Inc.Mar 2026$33.71M USD-3.7%-46.0%16.0%
NTRBNutriband Inc.Apr 2026$4.01M USD+35.2%+32.1%58.1%
Peer median (excluding ASRT) —-16.9%-7.2%51.3%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents36.81M64.94M73.44M50.59M10.23M
Short-term Investments00049.47M53.18M
Net Receivables43.75M45.36M47.66M54.12M120.11M
Inventory7.49M13.7M37.69M38.31M24.12M
Other Current Assets608K0299K10.07M9.01M
Total Current Assets103.5M132.26M171.06M202.55M216.65M
Property, Plant & Equipment (Net)2.26M881K2.04M1.71M444K
Goodwill00000
Intangible Assets216.05M198M111.33M80.47M48.91M
Long-term Investments1.58M268K000
Tax Assets080.2M000
Other Non-current Assets3.15M2.3M1.99M1K972K
Total Non-current Assets223.05M281.65M115.36M82.18M50.32M
Total Assets326.55M413.91M286.42M284.73M266.97M
Account Payables6.69M5.99M13.44M14.74M9.01M
Short-term Debt12.17M470K000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities47.65M30.37M6.09M96.36M118.5M
Total Current Liabilities135.02M95.32M93.44M114.69M127.51M
Long-term Debt61.32M66.4M38.21M38.81M39.12M
Deferred Tax Liabilities04.27M4.55M02.42M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities27.4M22.2M10.74M9.03M3.08M
Total Non-current Liabilities89.11M92.87M54.97M48.96M45.51M
Total Liabilities224.13M188.19M148.42M163.65M173.02M
Common Stock4K5K9K9K1K
Retained Earnings(429.23M)(319.6M)(651.54M)(673.12M)(703.5M)
Accumulated OCI00000
Other Stockholders Equity10000
Minority Interest00000
Total Equity102.41M225.73M138M121.08M93.95M
Total Debt75.87M66.87M39.68M40.27M40.01M
Net Debt39.06M1.93M(33.77M)(10.32M)29.78M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.